Search With Term
Recent Industry Update
- Adalimumab Biosimilar Litigation: Sandoz’s settlement with AbbVie
- Case Study – Quick Look up at DCGI approval of Lundbeck’s Brintellix
- Eyevance Pharmaceuticals Acquires Worldwide Rights to NEXAGON®
- Case Study: USFDA The Limited Population Pathway and approval of Arikayce
- Dr. Reddy’s sells Cloderm cream to EPI Health
- DRL to disinvest antibiotics plant to Abu Dhabi-based Neopharma
- Case Study: Product Recall due to labeling error
- Tildrakizumab (Ilumetri): Discovery, Development to Commercialization Case Study
- Consequences and progress of Takeda-Shire Buyout
- Indian health ministry banned 329 controversial fixed dose combination with immediate effect
- Pharma aaquisition: Aurobindo to acquire dermatology and oral solids businesses from Sandoz Inc. for $900 million
- Market Launch and brand positioning of Volini Maxx
- Grünenthal’s Duzallo: EU marketing authorization and Brand Positining
- USFDA approval of patisiran, first-of-its kind targeted RNA-based therapy
- Digital Strategy for pharma brand promotion: Merck launch map4health
- Insight on Novo Nordisk’s acquisition of Bristol, UK-based Ziylo for $800 million
- AstraZeneca’s Lynpraza got DCGI (India) marketing approval
- Pharma Packaging > How to convert IU to mg?
- Brand Promotion: Mankind’s OTC brand KABZEND
- PDL – Depomed’s deal for type 2 diabetes products
- EMA’s Prime Designation for Roche’s RG6042 – to treat Huntington’s disease
- In clinical research, is observational study is also known as interventional study?
- US FDA grants breakthrough therapy status for Lenvima in combo with Keytruda
- Insight on Bayer’s EU approval of new treatment regimen for Eylea
- Case Study: LEO Pharma’s acquisition of Bayer’s dermatology unit
- Wockhardt sets up $40-million antibiotic manufacturing plant in Jafza, Dubai
- What is USFDA – Field Alert Report (FAR) Submission for NDAs and ANDAs?
- EMA committee recommends approval of Merck’s Keytruda in combo with pemetrexed & platinum chemotherapy to treat metastatic nonsquamous NSCLC
- Daiichi Sankyo, Glycotope to develop gatipotuzumab antibody drug conjugate
- Hyrimoz Sandoz’s biosimilar got European marketing approval
Monthly Archieves
- October 2018 (7)
- September 2018 (4)
- August 2018 (14)
- July 2018 (34)
- June 2018 (2)
- May 2018 (14)
- April 2018 (8)
- March 2018 (7)
- February 2018 (6)
- January 2018 (6)
- December 2017 (9)
- November 2017 (9)
- October 2017 (14)
- September 2017 (12)
- August 2017 (12)
- July 2017 (11)
- June 2017 (12)
- May 2017 (18)
- April 2017 (11)
- March 2017 (20)
- February 2017 (15)
- January 2017 (12)
- December 2016 (23)
- November 2016 (20)
- October 2016 (7)
- September 2016 (15)
- August 2016 (21)
- July 2016 (36)
- June 2016 (20)
- May 2016 (24)
- April 2016 (21)
- March 2016 (27)
- February 2016 (24)
- January 2016 (19)
- December 2015 (8)
- November 2015 (16)
- October 2015 (25)
- September 2015 (22)
- August 2015 (12)
- July 2015 (32)
- June 2015 (33)
- May 2015 (32)
- April 2015 (19)
- March 2015 (10)
- February 2015 (17)
- January 2015 (33)
- December 2014 (41)
- November 2014 (20)
- October 2014 (10)
- September 2014 (10)